Table 1.
Cytotoxicity of BTZ, Ara-C and DSF/Cu2+ in AML cell lines
| Cell lines | AML Classification | Age | Type | IC50 (nM) (Mean ± SD) | ||
|---|---|---|---|---|---|---|
| BTZ | Ara-C | DSF/Cu2+ | ||||
| CMK | Acute Megakaryoblastic Leukemia | 10 months | Down Syndrome Relapse | 4.9 ± 2.6 | 70 ± 30 | 105 ± 25 |
| CMY | Acute Megakaryoblastic Leukemia | 21 months | Down SyndromeRefractory | 2.6 ± 0.6 | 1795 ± 391 | 72 ± 16 |
| CMS | Acute Megakaryoblastic Leukemia | 2 years | 4.3 ± 1.6 | 154 ± 21 | 82 ± 4.7 | |
| THP-1 | Acute Monocytic Leukemia MLL-AF9 | 1 year | Relapse | 7.8 ± 3.3 | 3537 ± 331 | 79 ± 18 |
| M-07e | Acute Megakaryoblastic Leukemia | 1 year | 3.7 ± 0.8 | 24 ± 4.4 | 68 ± 22 | |
| AML-193 | Acute Monocytic Leukemia | 13 years | Relapse | 4.6 ± 3.1 | 414 ± 29.9 | 53 ± 12.7 |
| Kasumi-1 | AML t(8,21) | 7 years | 2nd relapse after BMT | 6.7 ± 3.0 | 27.6 ± 2.5 | 89 ± 13 |
| Molm-13 | AML with Flt-3 ITD | 20 years | Relapse | 6.8 ± 3.6 | 4 ± 1 | 98 ± 10 |
| MV-4-11 | Biphenotypic Myelomonocytic Leukemia FLT-3 ITD | 10 years | 3.4 ± 0.5 | 278 ± 73 | 50 ± 10 | |
| NB4 | Acute Promyelocytic Leukemia | 20 years | Relapse | 2.7 ± 1.4 | 123 ± 114 | 57 ± 5 |
| HL-60 | Acute Promyelocytic Leukemia | 36 years | 7.1 ± 1.5 | 424 ± 172 | 67 ± 19 | |
| KG-1a | Acute Myeloid leukemia | 59 years | 17.0 ± 0.9 | 177 ± 43 | 79 ± 11 | |
| TF-1 | Erythroleukemia | 35 years | 8.3 ± 2.1 | 75 ± 52 | 101 ± 21 | |
| HEL 92.1.7 | Erythroleukemia | 30 years | 6.2 ± 2.9 | 102 ± 13 | 100 ± 8.5 | |
IC50 values are presented as mean ± standard deviation. Data represent at least three replicate experiments. Ara-C cytarabine, BTZ bortezomib, DSF disulfiram